HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.

Abstract
Tetrathiomolybdate is an anticopper drug with a unique mechanism of action. Tetrathiomolybdate complexes copper to protein and itself, rendering the copper unavailable for cellular uptake. It was originally developed for Wilson's disease, and is now being developed as an antiangiogenic agent for the treatment of cancer. Many angiogenic cytokines require normal levels of copper, and lowered copper levels reduce cytokine signaling while cellular copper requirements are met. Cytokines of fibrosis and inflammation may be similarly copper dependent, since tetrathiomolybdate inhibits bleomycin induced pulmonary inflammation and fibrosis. The basis for this inhibition was evaluated here by examination of tetrathiomolybdate effects on cytokines in lung pathophysiologically important in the bleomycin mouse model of pulmonary damage. Results in mice injected endotracheally with bleomycin confirmed that tetrathiomolybdate therapy was effective in reducing fibrosis. This effect was associated with significant inhibition of bleomycin-induced tumor necrosis factor alpha and transforming growth factor beta expression in lung homogenates. These effects were shown to be independent of one another. This indicates that tetrathiomolybdate therapy can be effective even when fibrosis is at a more chronic stage, wherein inflammatory cytokines are playing a diminishing role. The inhibition of tumor necrosis factor alpha suggests that diseases of tumor necrosis factor alpha overexpression are also potential targets of tetrathiomolybdate therapy.
AuthorsGeorge J Brewer, Robert Dick, Matthew R Ullenbruch, Hong Jin, Sem H Phan
JournalJournal of inorganic biochemistry (J Inorg Biochem) Vol. 98 Issue 12 Pg. 2160-7 (Dec 2004) ISSN: 0162-0134 [Print] United States
PMID15541506 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Angiogenesis Inhibitors
  • Cytokines
  • Bleomycin
  • Molybdenum
  • tetrathiomolybdate
  • Ceruloplasmin
Topics
  • Administration, Oral
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Animals
  • Bleomycin (toxicity)
  • Ceruloplasmin (analysis)
  • Cytokines (antagonists & inhibitors, drug effects)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Lung (drug effects, metabolism, pathology)
  • Mice
  • Mice, Inbred CBA
  • Molybdenum (administration & dosage, therapeutic use)
  • Pulmonary Fibrosis (chemically induced, pathology, prevention & control)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: